What is pathophysiology of Prostate cancer?

He aha te pathophysiology o te mate pukupuku repeure?

Ko te pathophysiology o te mate pukupuku o te repeure e pā ana ki ngā tikanga me ngā tukanga e arahi ana ki te whanaketanga me te haere o te mate.

Ko te mate pukupuku o te mate pukupuku he pukupuku kino e puta mai ana i nga pūtau o te repe prostate, he iti, he okana-ahua kei raro i te puku i roto i nga tane.

Ka whakaputaina e te repe repeure te wai tārai, e whāngai ana, e kawe ana i te kākano.

Kāore i te tino mōhiotia te take o te mate pukupuku repeure, engari he maha ngā take e mōhiotia ana e whakapiki ana i te mōrea o te whakawhanake i te mate.

Kei roto i ēnei ko te pakeke, te hītori whānau, te iwi, me ētahi iranga iranga.

Ko te mate pukupuku o te repeure he tino noa i roto i nga tane pakeke, me te nuinga o nga take e puta ana i nga tane i runga ake i te 65 tau.

Hei taapiri, ko nga tane he hitori o te mate pukupuku o te repeure i roto i o ratau whanau, he nui ake te tuponotanga, pera ano i nga tane o Awherika o Amerika me nga taangata o te Karipiana.

Ko te pathophysiology o te mate pukupuku repeure e pa ana ki te tipu kore me te wehenga o nga pūtau i roto i te repeure repeure.

Ka puta pea tēnei nā ngā irakētanga iranga e ahu atu ana ki te whakapuakitanga o ētahi āhuatanga tupu, te whakakore rānei i ngā ira whakakāhoretanga puku.

Ka puta ēnei irakētanga i te tipu kore o ngā pūtau, e ahu ana ki te hanganga o te puku.

I te tipu o te puku, ka taea e ia te whakaeke i nga kiko me nga okana tata, penei i te mimi, te puku, me nga puku lymph tata.

I ētahi wā, ka taea e ngā pūtau mate pukupuku te wehe atu i te puku tuatahi, ka hora ki ētahi atu wāhanga o te tinana mā te toto, te pūnaha lymphatic rānei, he tukanga e mōhiotia ana ko te metastasis.

Ina horapa te mate pukupuku, ka uaua ake te whakaora.

Ka taea hoki te whakaawe i te mate pukupuku o te repeure e nga take homoni, otirā ko te testosterone hormone androgen.

Ka taea e te testosterone te whakaongaonga i te tipu o nga pūtau mate pukupuku repeure, me te maha o nga maimoatanga mo te mate pukupuku repeure e whai ana ki te whakaiti i nga taumata o tenei homoni, ki te aukati ranei i ona hua.

Hei whakarāpopototanga, ko te pathophysiology o te mate pukupuku repeure e pā ana ki te tipu me te wehenga kore o nga pūtau i roto i te repeure, ka taea te whakaaweawe e nga take iranga, hormonal, taiao hoki.

Ko te mārama ki ngā tikanga o te mate he mea nui ki te whakawhanake i ngā maimoatanga whai hua me te whakapai ake i ngā hua mō ngā tūroro me te mate pukupuku pukupuku.

['Ngā tohutoro']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Zobniw CM, Causebrook A, Fong MK: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014, 6 (): 97-105.

Lim HY, Agarwal AM, Agarwal N, Ward JH: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J. 2009, 50 (5): e178-80.

Kohli M, Qin R, Jimenez R, Dehm SM: Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012, 2012 (): 781459.

Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995, 1 (9): 944-9.

Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M: Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs. 2013, 22 (11): 1385-400.

Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013, 23 (5): 313-9.

Jadvar H: Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. , 8 (2): 56-64.

['Whakakahoretanga: hauora']

['Ko tenei paetukutuku e whakaratohia ana mo nga kaupapa ako me nga korero anake, kaore hoki e whakarato i nga tohutohu hauora, i nga ratonga ngaio ranei.']

['Kaua e whakamahia ngā mōhiohio e whakaratohia ana hei tātaritanga, hei whakaora rānei i tētahi raruraru hauora, mate rānei, ā, ko te hunga e rapu ana i te tohutohu hauora whaiaro me kōrero ki tētahi tākuta whai raihana.']

['Kia mōhio mai koe ko te whatunga pūtau e whakaputa ana i ngā whakautu ki ngā pātai, he tino hē ina tae mai ki te ihirangi tau. Hei tauira, ko te tokomaha o ngā tāngata kua tohua he mate tauwhāiti.']

['Me rapu tonu i te tohutohu a tō tākuta, i tētahi atu kaiwhakarato hauora whai tohu rānei e pā ana ki tētahi mate hauora. Kaua rawa e whakahawea ki te tohutohu hauora ngaio, te whakaroa rānei ki te rapu i te mea nā tētahi mea i pānuihia e koe i tēnei paetukutuku. Ki te whakaaro koe he mate hauora ohorere pea koe, waea atu ki te 911 ka haere ki te rūma ohorere tata tonu. Kāore he hononga tākuta-tūroro i hangaia e tēnei paetukutuku, i tōna whakamahinga rānei. Kāore a BioMedLib, ōna kaimahi rānei, tētahi kaitohutohu rānei ki tēnei paetukutuku, e whakaatu ana, e tohu ana rānei, e pā ana ki ngā mōhiohio e whakaratohia ana i konei, ki tōna whakamahinga rānei.']

['Whakakahoretanga: mana pupuri']

['Ko te Ture Mana pupuri Mamati Mamati o te tau 1998, 17 U.S.C. § 512 (te DMCA) e whakarato ana i te whakahoki mo nga rangatira mana pupuri e whakapono ana ko nga rauemi e puta ana i runga i te Ipurangi e takahi ana i o raatau mana i raro i te ture mana pupuri a US. ']

['Mēnā e whakapono pono ana koe e takahi ana tētahi ihirangi, rauemi rānei e wātea ana i runga i tō mātou paetukutuku, ratonga rānei i tō mana pupuri, ka taea e koe (tō māngai rānei) te tuku pānui ki a mātou e tono ana kia tangohia te ihirangi, rauemi rānei, kia āraia rānei te uru atu ki a ia. ']

["Me tuku ngā whakamōhiotanga ā-tuhi mā te īmēra (tirohia te wāhanga 'Whakapā' mō te wāhitau īmēra). "]

['E hiahiatia ana e te DMCA kia whakaurua ki tō whakamōhiotanga mō te whakawātea mana pupuri i ngā mōhiohio e whai ake nei: (1) whakaahuatanga o te mahi mana pupuri e pā ana ki te whakawātea e whakapaetia ana; (2) whakaahuatanga o te ihirangi e whakapaetia ana e takahi ana me ngā mōhiohio e tika ana kia taea ai e mātou te kimi i te ihirangi; (3) mōhiohio whakapā mōu, tae atu ki tō wāhitau, tau waea me tō wāhitau īmēra; (4) he tauākī nāu e whakapono pono ana koe kāore te ihirangi i te āhua e amuamutia ana i whakamanahia e te kaipupuri mana pupuri, e tana māngai rānei, e te whakahaerenga rānei o tētahi ture; ']

['(5) he tauākī nāu i haina, i raro i te whiu o te whakapae teka, e tika ana ngā mōhiohio i roto i te whakamōhiotanga, ā, kei a koe te mana ki te whakatinana i ngā mana pupuri e kīia ana kua takahia;']

['me te (6) he waitohu ā-tinana, ā-rorohiko rānei a te kaipupuri mana pupuri, a tētahi tangata rānei kua whakamanahia ki te mahi mō te kaipupuri mana pupuri. ']

['Ki te kore e whakaurua ngā mōhiohio katoa i runga ake nei, ka whakaroa pea te tukatuka o tō amuamu.']

['Whakapā']

['Tena koa tukuna mai he imeera ki a maatau me tetahi patai / whakaaro.']

What is pathophysiology of prostate cancer?

The pathophysiology of prostate cancer refers to the underlying mechanisms and processes that lead to the development and progression of the disease.

Prostate cancer is a malignant tumor that arises from the cells of the prostate gland, which is a small, walnut-shaped organ located below the bladder in men.

The prostate gland produces seminal fluid, which nourishes and transports sperm.

The exact cause of prostate cancer is not fully understood, but several factors are known to increase the risk of developing the disease.

These include age, family history, race, and certain genetic mutations.

Prostate cancer is more common in older men, with the majority of cases occurring in men over the age of 65.

Additionally, men with a family history of prostate cancer are at an increased risk, as are African American men and men of Caribbean descent.

The pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland.

This can occur due to genetic mutations that lead to the overexpression of certain growth factors or the inactivation of tumor suppressor genes.

These mutations can result in the unregulated growth of cells, leading to the formation of a tumor.

As the tumor grows, it can invade nearby tissues and organs, such as the bladder, rectum, and nearby lymph nodes.

In some cases, cancer cells can break away from the primary tumor and spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.

Once the cancer has spread, it can be more difficult to treat.

Prostate cancer can also be influenced by hormonal factors, particularly the androgen hormone testosterone.

Testosterone can stimulate the growth of prostate cancer cells, and many treatments for prostate cancer aim to reduce the levels of this hormone or block its effects.

In summary, the pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland, which can be influenced by genetic, hormonal, and environmental factors.

Understanding the underlying mechanisms of the disease is crucial for developing effective treatments and improving outcomes for patients with prostate cancer.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.